Organization | Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany

Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Frankfurt Germany (1991)

Organization Overview

First Clinical Trial

1997

NCT00017225

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany

Active Ingredients

Drugs in Phase 4 Trials (4)

carboplatin (paraplatin) (5 trials)

cisplatin (platinol) (5 trials)

etoposide (vepesid) (8 trials)

ifosfamide (ifex) (6 trials)

Drugs in Phase 3 Trials (19)

autologous hematopoietic stem cells (4 trials)

busulfan (Myleran) (1 trial)

cyclophosphamide (cytoxan) (5 trials)

dacarbazine (dtic-dome) (3 trials)

dactinomycin (cosmegen) (2 trials)

dexamethasone (1 trial)

doxorubicin (Doxil) (6 trials)

idarubicin (idamycin) (1 trial)

imatinib (gleevec) (1 trial)

inotuzumab ozogamicin (besponsa) (1 trial)

iobenguane sulfate i-131 (2 trials)

isotretinoin (Accutane) (2 trials)

lomustine (1 trial)

melphalan (alkeran) (4 trials)

naltrexone (revia) (1 trial)

prednisone (meticorten) (1 trial)

sargramostim (leukine) (3 trials)

topotecan (hycamtin) (2 trials)

vincristine (oncovin) (7 trials)

Drugs in Phase 2 Trials (2)

bone autograft (1 trial)

tretinoin (Retin-A) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Central Nervous System Neoplasms (Phase 3)

Glioma (Phase 3)

Kidney Neoplasms (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Neoplasms, Germ Cell and Embryonal (Phase 4)

Nervous System Neoplasms (Phase 3)

Neuroblastoma (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Rhabdomyosarcoma (Phase 3)

Sarcoma (Phase 3)

Wilms Tumor (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial APIs: 25